Privately-held cell therapy company Orca Bio has announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking approval for ...

US biotech AeroRx Therapeutics has secured $21 million in series A financing to advance its lead program, AERO-007, into Phase IIb testing in chronic obstructive pulmonary disease. The round was led ...

The ground shifted under China’s drugmakers when volume-based procurement cut through list prices. Margins tightened, business models wobbled, and strategy decks were rewritten overnight. The domestic ...

Massachusetts, USA-based Affinia Therapeutics, an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating ...

Dutch biotech uniQure recently announced that its novel gene therapy, AMT-130 (ifezuntirgene inilparvovec), demonstrated statistically-significant disease slowing in a Huntington’s disease (HD) ...

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, today announced the appointment of Cristina Oliva as chief medical officer (CMO). Dr Oliva is a ...

Belgian biotech Bioxodes has appointed Philippe Monteyne as chairman of its board, replacing Pierre Detrixhe. The move comes ...

The atrial fibrillation (AF) market across the eight major markets (8MM) is forecast to decline at a negative compound annual ...

Skye Bioscience (Nasdaq: SKYE) reported topline data from a mid-stage trial showing that its obesity drug nimacimab failed to cut weight on its own but added meaningful benefit when paired with Novo ...

US lobby group Pharmaceutical Research and Manufacturers of America (PhRMA) revealed that member companies, thanks to ...

Australian biotech Neurizon Therapeutics (ASX: NUZ) said the US regulator has lifted the clinical hold on its lead drug ...

Oxford, UK-based clinical-stage biotech Theolytics today announced the appointment of Dr Matilde Saggese, as chief medical ...